Soluble ActRIIa Antagonists for Bone Density and Strength
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for bone disorders such as osteoporosis often come with undesirable side effects and fail to effectively promote bone growth and increase bone density, as they primarily act as either anti-catabolic or anabolic agents without dual activity.
Innovation Solution
The use of activin or ActRIIa antagonists, specifically soluble ActRIIa proteins, which exhibit dual catabolic and anabolic effects by inhibiting activin-ActRIIa signaling, promoting increased bone density and strength without significantly affecting muscle mass.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-catabolic or anabolic agents are used to treat bone disorders, then bone growth or bone density improvement is achieved, but undesirable side effects occur and the agents lack dual activity
Solution Approach 1:
The patent uses soluble ActRIIa protein as an intermediary substance that mediates between activin and its receptor. This soluble receptor acts as a decoy, binding activin without triggering the harmful signaling pathway, thereby blocking the harmful effect while preserving the beneficial bone growth promotion through dual catabolic and anabolic activity
Solution Approach 2:
The patent changes the parameter of ActRIIa from a membrane-bound form to a soluble form. This parameter change allows the receptor to be released into the circulation, enabling it to act as a circulating antagonist that can bind activin in the extracellular space and prevent its binding to membrane-bound receptors, thus resolving the contradiction between effectiveness and side effects
2Strength
If anti-activin A antibody is administered to inhibit activin-ActRIIa signaling, then bone density and strength increase, but the mechanism requires specific binding inhibition
Solution Approach 1:
The patent extracts the ActRIIa receptor from the cell membrane and presents it in soluble form. This extraction allows the receptor to be removed from the membrane-bound signaling complex and function as a free-floating inhibitor that binds activin in the extracellular space, simplifying the mechanism by which bone strength is enhanced without requiring complex membrane receptor modulation
Data Source
AI summary
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.